NDA 206977 · Ibsa
Tirosint-Sol
Levothyroxine Sodium · Oral
Last checked: Nov 21, 2026Latest source record: Nov 16, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2016
Dec 15, 2016
Approved uses
1
Original approval plus efficacy supplements
Registered trials
216
36 Phase 3, 17 recruiting
FAERS reports
105,950
71,861 serious, 8,452 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS Thyroid hormones, including TIROSINT-SOL, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects [see Adverse Reactions (6) , Drug Interactions (7.7) , and Overdosage (10) ]. WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS See full prescribing information for complete boxed warning Thyroid hormones, including TIROSINT-SOL, should not be used for the treatment of obesity or for weight loss. Doses beyond the range of daily hormonal requirements may produce...
What it is approved for
From the label in effect Mar 27, 2026.
1 INDICATION AND USAGE TIROSINT-SOL is L-thyroxine (T4) indicated in adult and pediatric patients, including neonates, for: Hypothyroidism - As replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism ( 1 ) Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression - As an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer ( 1 ) Limitations of Use Not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients ( 1 ) Not indicated for treatment of transient hypothyroidism during the recovery phase of subacute thyroiditis ( 1 ) Hypothyroidism TIROSINT-SOL is indicated in adult and pediatric patients, including neonates, as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression TIROSINT-SOL is indicated in adult and pediatric patients, including neonates, as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. Limitations of Use Tirosint-SOL is not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatment with TIROSINT-SOL may induce hyperthyroidism [see Warnings and Precautions (5.1) ] . Tirosint-SOL is not indicated for treatment of transient hypothyroidism during the recovery phase of subacute thyroiditis.
Mechanism: Thyroid hormones exert their physiologic actions through control of DNA transcription and protein synthesis. Triiodothyronine (T3) and L-thyroxine (T4) diffuse into the cell nucleus and bind to thyroid receptor proteins attached to DNA. This hormone nuclear receptor complex activates gene transcription and synthesis of messenger RNA and cytoplasmic proteins. The physiological actions of thyroid hormones are produced predominantly by T3, the majority of which (approximately 80%) is derived from T4 by deiodination in peripheral tissues.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
15 products under this application
- TIROSINT-SOL · LEVOTHYROXINE SODIUM 137MCG/ML · SOLUTION, ORAL · Prescription
- TIROSINT-SOL · LEVOTHYROXINE SODIUM 62.5MCG/ML · SOLUTION, ORAL · Prescription
- TIROSINT-SOL · LEVOTHYROXINE SODIUM 112MCG/ML · SOLUTION, ORAL · Prescription
- TIROSINT-SOL · LEVOTHYROXINE SODIUM 37.5MCG/ML · SOLUTION, ORAL · Prescription
- TIROSINT-SOL · LEVOTHYROXINE SODIUM 88MCG/ML · SOLUTION, ORAL · Prescription
- TIROSINT-SOL · LEVOTHYROXINE SODIUM 175MCG/ML · SOLUTION, ORAL · Prescription
- TIROSINT-SOL · LEVOTHYROXINE SODIUM 50MCG/ML · SOLUTION, ORAL · Prescription
- TIROSINT-SOL · LEVOTHYROXINE SODIUM 13MCG/ML · SOLUTION, ORAL · Prescription
- TIROSINT-SOL · LEVOTHYROXINE SODIUM 125MCG/ML · SOLUTION, ORAL · Prescription
- TIROSINT-SOL · LEVOTHYROXINE SODIUM 44MCG/ML · SOLUTION, ORAL · Prescription
- TIROSINT-SOL · LEVOTHYROXINE SODIUM 100MCG/ML · SOLUTION, ORAL · Prescription
- TIROSINT-SOL · LEVOTHYROXINE SODIUM 200MCG/ML · SOLUTION, ORAL · Prescription
- TIROSINT-SOL · LEVOTHYROXINE SODIUM 75MCG/ML · SOLUTION, ORAL · Prescription
- TIROSINT-SOL · LEVOTHYROXINE SODIUM 150MCG/ML · SOLUTION, ORAL · Prescription
- TIROSINT-SOL · LEVOTHYROXINE SODIUM 25MCG/ML · SOLUTION, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Levothyroxine" as an intervention, any sponsor and status, largest first.
- Thyroid Disease in Pregnancy: Case Finding Versus Universal ScreeningPivotal-lookingCompleted
Ospedale V. FazziAcademic, hospital or other
NCT00846755 · 4,657 participants · Start Mar 2005 · Primary completion Mar 2008
Drug: Levothyroxine, Propylthiouracile · For: Thyroid Disease; Pregnancy
Sites: Lecce, Italy
- Sequenced Treatment Alternatives to Relieve Depression (STAR*D)Pivotal-lookingCompleted
National Institute of Mental Health (NIMH)NIH
NCT00021528 · 4,000 participants · Start Jul 2001
Drug: citalopram; BuproprionSR and 8 more · For: Depression
Sites: Birmingham, Alabama; Tuscaloosa, Alabama; Chula Vista, California · 41 sites in all
- A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult ParticipantsPivotal-lookingActive, not recruiting
AbbVieAbbVie (ABBV)
NCT06345339 · 2,701 participants · Start Apr 26, 2024 · Primary completion Sep 2027
Drug: Armour Thyroid; Levothyroxine · For: Hypothyroidism
Sites: Birmingham, Alabama; Bonita, California; Burbank, California · 139 sites in all
- Thyroid Therapy for Mild Thyroid Deficiency in PregnancyPivotal-lookingCompleted
The George Washington University Biostatistics CenterAcademic, hospital or other
NCT00388297 · 1,203 participants · Start Oct 2006 · Primary completion Aug 2015
Drug: Levothyroxine; Placebo for Levothyroxine · For: Subclinical Hypothyroidism; Hypothyroxinemia; Pregnancy
Sites: Birmingham, Alabama; Chicago, Illinois; Detroit, Michigan · 14 sites in all
- LISA-study : Levothyroxin in Nodular GoiterPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT00277589 · 1,024 participants · Start May 2004 · Primary completion Dec 2008
Drug: Levothyroxin-Na; Levothyroxine-Na + iodide and 2 more · For: Goiter, Nodular
Sites: Frankfurt, Germany
- Intravenous Thyroxine for Heart-Eligible Organ DonorsPivotal-lookingCompleted
Washington University School of MedicineAcademic, hospital or other
NCT04415658 · 838 participants · Start Dec 1, 2020 · Primary completion Nov 6, 2022
Drug: Thyroxine; Saline · For: Brain Death; Heart Failure
Sites: Phoenix, Arizona; San Diego, California; Denver, Colorado · 14 sites in all
- Effect of HCQ Combined With LT4 on LBR in Euthyroid Women With URPL and TPO-AbPivotal-lookingRecruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityAcademic, hospital or other
NCT06652113 · 796 participants (planned) · Start Nov 15, 2024 · Primary completion Mar 2035
Drug: hydroxychloroquine and levothyroxine; Levothyroxine · For: Recurrent Pregnancy Loss; Euthyroid With Thyroid Antibodies
Sites: Guangzhou, China · 2 sites in all
- Differentiated Thyroid Cancer: is There a Need for Radioiodine Ablation in Low Risk Patients?Pivotal-lookingActive, not recruiting
Gustave Roussy, Cancer Campus, Grand ParisAcademic, hospital or other
NCT01837745 · 776 participants · Start May 13, 2013 · Primary completion Apr 1, 2022
Drug: rhTSH stimulation; I131 · For: Low Risk Differentiated Thyroid Cancer
Sites: Villejuif, France
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fatigue8,794
- nausea7,563
- diarrhoea6,822
- headache6,722
- dyspnoea6,540
- drug ineffective5,752
- pain5,521
- dizziness5,325
- vomiting4,644
- asthenia4,534
- malaise4,354
- off label use4,266
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 2,043 |
| 2005 | 2,018 |
| 2006 | 2,180 |
| 2007 | 2,761 |
| 2008 | 4,015 |
| 2009 | 3,824 |
| 2010 | 4,310 |
| 2011 | 6,158 |
| 2012 | 6,850 |
| 2013 | 1,453 |
| 2014 | 1,810 |
| 2015 | 2,608 |
| 2016 | 3,443 |
| 2017 | 3,901 |
| 2018 | 4,524 |
| 2019 | 4,399 |
| 2020 | 5,903 |
| 2021 | 6,176 |
| 2022 | 7,733 |
| 2023 | 7,405 |
| 2024 | 7,735 |
| 2025 | 8,648 |
| 2026 | 6,052 |
Recalls
15 FDA enforcement reports for this application.
Jan 30, 2023 · Class II · Terminated
Subpotent Drug
Jan 30, 2023 · Class II · Terminated
Subpotent Drug
Jan 30, 2023 · Class II · Terminated
Subpotent Drug
Jan 30, 2023 · Class II · Terminated
Subpotent Drug
Jan 30, 2023 · Class II · Terminated
Subpotent Drug
Jan 30, 2023 · Class II · Terminated
Subpotent Drug
Jan 30, 2023 · Class II · Terminated
Subpotent Drug
Jan 30, 2023 · Class II · Terminated
Subpotent Drug
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Tirosint-Sol (Levothyroxine Sodium)
2024 spending
$2.6M
Beneficiaries
2,457
11,238 claims
Per beneficiary
$1,059
$4.63 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $974,450 |
| 2021 | $1,491,858 |
| 2022 | $1,997,718 |
| 2023 | $1,876,820 |
| 2024 | $2,602,064 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Fasting vs Nonfasting, Dose-adjusted Levothyroxine Ingestion in Hypothyroidism: A Randomized Clinical Trial.
Willems JIA, van Twist DJL, Helmich F, et al. · J Clin Endocrinol Metab 2026 · Randomized Controlled Trial, Comparative Study
- Comparative Effectiveness of Levothyroxine, Desiccated Thyroid Extract, and Levothyroxine+Liothyronine in Hypothyroidism.
Shakir MKM, Brooks DI, McAninch EA, et al. · J Clin Endocrinol Metab 2021 · Comparative Study, Randomized Controlled Trial
- Treatment Preferences in Patients With Hypothyroidism.
de Lima Beltrão FE, Carvalhal G, de Almeida Beltrão DC, et al. · J Clin Endocrinol Metab 2025 · Meta-Analysis, Network Meta-Analysis
- Effects of Levothyroxine Treatment on Fertility and Pregnancy Outcomes in Subclinical Hypothyroidism: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Sankoda A, Suzuki H, Imaizumi M, et al. · Thyroid 2024 · Meta-Analysis, Systematic Review
- Association between primary hypothyroidism and metabolic dysfunction-associated steatotic liver disease: an updated meta-analysis.
Mantovani A, Csermely A, Bilson J, et al. · Gut 2024 · Meta-Analysis, Systematic Review
- Clinical efficacy of selenium supplementation in patients with Hashimoto thyroiditis: A systematic review and meta-analysis.
Zhang H, Yang Y, Liu S, et al. · Medicine (Baltimore) 2025 · Systematic Review, Meta-Analysis
Sponsor: Ibsa
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.